Stock AnalizInnospec Inc. IOSP
Major Chemicals · data as of November 13, 2026
Innospec Inc. (IOSP) is a industrial company listed in the US with a market value of about $2.0B. In the twelve months to September 30, 2026 it had revenue of $1.9B and net income of $140M, a net margin of 7.5%.
Its overall Stock Analiz score is 3.2 out of 5 (average). The strongest part is financial health (5/5); the weakest is future growth (2/5).
Key numbers: a P/E of 14.2, a price to free cash flow of 43.4, 5-year revenue growth of 8% a year, a 5-year average ROIC of 10%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 28% below the current price.
Score: 3.2 / 5
Checks passed
- P/E below 25
- P/E below the industry median
- PEG below 1.5
- Profit margin improving
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year revenue growth above 8% a year
- Profitable 5 years in a row
Checks not passed
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Strong R&D investment or growth above 20%
- 5-year average ROIC above 12%
- ROE above 15%
- Share count down over 3 years (buybacks)
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.9B | $1.8B | $1.8B | $1.9B | $2.0B | $1.5B | $1.2B | $1.5B | $1.5B | $1.3B | $883M |
| Net income | $140M | $117M | $36M | $139M | $133M | $93M | $29M | $112M | $85M | $62M | $81M |
| Free cash flow | $46M | $88M | $143M | $145M | $42M | $54M | $116M | $132M | $76M | $59M | $89M |
| EPS (diluted) | $5.67 | $4.67 | $1.42 | $5.56 | $5.32 | $3.75 | $1.16 | $4.54 | $3.45 | $2.52 | $3.33 |
| Net margin | 7.5% | 6.6% | 1.9% | 7.1% | 6.8% | 6.3% | 2.4% | 7.4% | 5.8% | 4.7% | 9.2% |
| ROIC | — | 7.9% | 12.2% | 10.8% | 12.5% | 8.6% | 2.5% | 11.1% | 8.3% | 9.8% | 8.4% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 3 analysts is $99.33, 24% above the current price; targets range from $93.00 to $110.00; the consensus rating is “Strong buy”; expected EPS is $5.04 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is Innospec’s P/E ratio?
About 14.2, based on the last twelve months of diluted earnings per share (forward P/E about 13.8).
Is Innospec stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 28% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Innospec pay a dividend?
Yes. The dividend yield is about 2.40%, and it has paid dividends for 10 years in our data.
Is Innospec a good stock to buy?
We do not give buy or sell advice. Innospec scores 3.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.